{"id":28863,"date":"2021-08-27T11:41:43","date_gmt":"2021-08-27T03:41:43","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=28863"},"modified":"2023-11-13T12:17:02","modified_gmt":"2023-11-13T04:17:02","slug":"%e4%ba%baegf%e8%a1%a8%e9%9d%a2%e7%94%9f%e9%95%b7%e5%9b%a0%e5%ad%90elisa%e8%a9%a6%e5%8a%91%e7%9b%92-elikine-human-egf-elisa-kit%e8%b2%a8%e8%99%9fkte70003","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=28863","title":{"rendered":"\u4ebaEGF\u8868\u9762\u751f\u9577\u56e0\u5b50ELISA\u8a66\u5291\u76d2 | EliKine\u2122 Human EGF ELISA Kit\u8ca8\u865fKTE6005"},"content":{"rendered":"

\u4ebaEGF\u8868\u9762\u751f\u9577\u56e0\u5b50\uff08Epidermal growth factor, EGF\uff09ELISA\u8a66\u5291\u76d2 | <\/strong>EliKine\u2122 Human EGF ELISA Kit\u8ca8\u865fKTE6005<\/strong><\/span>\u00a0<\/a><\/span>\u00a03.9 pg\/mL-250 pg\/mL<\/u><\/strong>, \u6700\u4f4e\u9748\u654f\u5ea62 pg\/ml<\/u><\/strong><\/span><\/span><\/p>\n

<\/p>\n

\u4eba EGF \u662f EGF \u524d\u9ad4\u7d30\u80de\u5916\u7d50\u69cb\u57df\u7684 53 \u500b\u6c28\u57fa\u9178\u9577\u7247\u6bb5\u3002\u4f5c\u70ba\u5176\u4ed6\u7d44 1 \u6210\u54e1(r group 1 members)\uff0cEGF \u7d50\u5408\u4e26\u6fc0\u6d3b(activates) EGF \u53d7\u9ad4\u3002\u9019\u4fc3\u9032\u4e86EGFR\u4e8c\u805a\u5316(EGFR dimerization)\u3002 EGF \u5177\u6709\u591a\u7a2e\u4e0d\u540c\u7684\u751f\u7406\u4f5c\u7528\u3002 EGF \u6d3b\u6027\u7531\u65bc\u5176\u4ed6 EGF \u5bb6\u65cf\u6210\u54e1\u5229\u7528 EGF \u53d7\u9ad4\u800c\u8b8a\u5f97\u8907\u96dc\u3002 EGF \u5728\u9ad4\u5167\u548c\u9ad4\u5916\u523a\u6fc0\u5404\u7a2e\u8868\u76ae(epidermal)\u548c\u4e0a\u76ae(epithelial)\u7d44\u7e54\u4ee5\u53ca\u7d30\u80de\u57f9\u990a\u7269\u4e2d\u67d0\u4e9b\u6210\u7e96\u7dad\u7d30\u80de(fibroblasts)\u7684\u751f\u9577\u3002 EGF \u88ab\u63d0\u8b70\u5f71\u97ff\u8a31\u591a\u5176\u4ed6\u80ce\u5152(fetal)\u548c\u6210\u4eba\u7d44\u7e54(adult tissues)\u7684\u751f\u9577(growth)\u548c\/\u6216\u5206\u5316(differentiation)\u3002<\/p>\n

EGF\u8868\u9762\u751f\u9577\u56e0\u5b50ELISA\u8a66\u5291\u76d2\u63a1\u7528\u5169\u9ede\u593e\u5fc3ELISA(Sandwich ELISA)\u5b9a\u91cf\u6a23\u54c1\u4e2d\u7684EGF\u8868\u9762\u751f\u9577\u56e0\u5b50\uff08Epidermal growth factor, EGF\uff09\u3002\u5c0dEGF\u8868\u9762\u751f\u9577\u56e0\u5b50\uff08Epidermal growth factor, EGF\uff09\u7279\u7570\u7684\u6297\u9ad4\u5df2\u9810\u5148\u5305\u88ab\u5728\u5fae\u5b54\u677f\u4e0a\u3002\u5c07\u6a19\u6e96\u54c1\u548c\u6a23\u54c1\u5438\u53d6\u5230\u5b54\u4e2d\uff0c\u4e26\u4e14\u5b58\u5728\u7684\u4efb\u4f55EGF\u8868\u9762\u751f\u9577\u56e0\u5b50\uff08Epidermal growth factor, EGF\uff09\u90fd\u88ab\u56fa\u5b9a\u7684\u6297\u9ad4\u7d50\u5408\u3002\u9664\u53bb\u6240\u6709\u672a\u7d50\u5408\u7684\u7269\u8cea\u5f8c\uff0c\u5c07 biotin-conjugated antibody specific -EGF\u8868\u9762\u751f\u9577\u56e0\u5b50\uff08Epidermal growth factor, EGF\uff09\u6aa2\u6e2c\u6297\u9ad4\u6dfb\u52a0\u5230\u5b54\u4e2d\u3002\u6d17\u6ecc\u4ee5\u9664\u53bb\u4efb\u4f55\u672a\u7d50\u5408\u7684\u8a66\u5291\u5f8c\uff0c\u5c07 EliKine\u2122 Streptavidin-HRP conjugates\u6dfb\u52a0\u5230\u5b54\u4e2d\uff0c\u4e26\u4e14\u6839\u64da\u5728\u521d\u59cb\u6b65\u9a5f\u4e2d\u7d50\u5408\u7684EGF\u8868\u9762\u751f\u9577\u56e0\u5b50\uff08Epidermal growth factor, EGF\uff09\u7684\u91cf\u6210\u6bd4\u4f8b\u5730\u986f\u8272\u3002\u505c\u6b62\u986f\u8272\u4e26\u6e2c\u91cf\u984f\u8272\u7684\u5f37\u5ea6\u3002\u5075\u6e2c\u7bc4\u570d: 3.9 pg\/mL-250 pg\/mL<\/u><\/strong>, \u6700\u4f4e\u9748\u654f\u5ea62 pg\/Ml<\/u><\/strong>\u3002<\/u><\/strong>\u53ef\u61c9\u7528\u65bc\u4ee5\u4e0b\u6a23\u54c1\u4f86\u6e90: Cell culture supernatants, Other biological fluids, Plasma, Serum<\/p>\n

<\/p>\n

EliKine\u2122 Human EGF ELISA Kit employs a two-site sandwich ELISA to quantitate EGF in samples. An antibody specific for EGF has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any EGF present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for EGF is added to the wells. After washing, proprietary EliKine\u2122 Streptavidin-HRP conjugates is added to the wells. Following a wash to remove any unbound streptavidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of EGF bound in the initial step. The color development is stopped and the intensity of the color is measured.<\/p>\n

\"EGF<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Product name<\/strong><\/td>\nEliKine\u2122 Human EGF ELISA Kit<\/td>\n<\/tr>\n
Reactivity<\/strong><\/td>\nHuman<\/td>\n<\/tr>\n
Applications<\/strong><\/td>\nELISA<\/td>\n<\/tr>\n
Detection method<\/strong><\/td>\nColorimetric<\/td>\n<\/tr>\n
SampleType<\/strong><\/td>\nCell culture supernatants, Other biological fluids, Plasma, Serum<\/td>\n<\/tr>\n
Assay type<\/strong><\/td>\nSandwich ELISA (quantitative)<\/td>\n<\/tr>\n
Assay duration<\/strong><\/td>\nMultiple steps standard sandwich ELISA assay with a working time of 3-5 hours. It depends on the experience of the operation person.<\/td>\n<\/tr>\n
Alternative<\/strong><\/td>\nBeta urogastrone; Epidermal growth factor; HOMG4; OTTHUMP00000219721; OTTHUMP00000219722; Pro epidermal growth factor; URG; Urogastrone<\/td>\n<\/tr>\n
\u00a0<\/strong><\/td>\n<\/td>\n<\/tr>\n
Kit components<\/strong><\/td>\n\u2022 Human EGF microplate
\n\u2022 Human EGF standard
\n\u2022 Human EGF detect antibody
\n\u2022 Avidin-HRP
\n\u2022 Standard diluent
\n\u2022 Assay buffer
\n\u2022 HRP substrate
\n\u2022 Stop solution
\n\u2022 Wash buffer
\n\u2022 Plate covers.<\/td>\n<\/tr>\n
Features & Benefits<\/strong><\/td>\nEliKine\u2122 Human EGF ELISA Kit has high sensitivity and excellent specificity for detection of Human EGF. No significant cross-reactivity or interference between Human EGF and analogues was observed.<\/td>\n<\/tr>\n
Calibration range<\/strong><\/td>\n3.9 pg\/mL-250 pg\/mL<\/td>\n<\/tr>\n
Limit of detection<\/strong><\/td>\n2 pg\/Ml<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u9175\u7d20\u9023\u7d50\u514d\u75ab\u5438\u9644\u6e2c\u5b9a\u6cd5\uff08ELISA\uff09\u662f\u4e00\u7a2e\u5e38\u7528\u65bc\u6e2c\u91cf\u751f\u7269\u6a23\u672c\u4e2d\u7684\u6297\u9ad4(antibodies)\u3001\u6297\u539f( antigens)\u3001\u86cb\u767d\u8cea(proteins)\u548c\u7cd6\u86cb\u767d( glycoproteins )\u7684\u514d\u75ab\u5b78\u6e2c\u5b9a\u3002\u4e00\u4e9b\u4f8b\u5b50\u5305\u62ec\uff1aHIV \u611f\u67d3( HIV infection)\u7684\u8a3a\u65b7\u3001\u598a\u5a20\u8a66\u9a57(pregnancy tests)\u4ee5\u53ca\u7d30\u80de\u4e0a\u6e05\u6db2\u6216\u8840\u6e05\u4e2d\u7d30\u80de\u56e0\u5b50(cytokines)\u6216\u53ef\u6eb6\u6027\u53d7\u9ad4(soluble receptors)\u7684\u6e2c\u91cf\u3002 ELISA\u539f\u7406\u53ef\u5206\u70ba\u593e\u5fc3ELISA(sandwich ELISA)\u3001\u7af6\u722d\u6027ELISA(competitive ELISA )\u548c\u9593\u63a5ELISA(competitive ELISA )\u3002<\/p>\n

<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716_\u5de5\u4f5c\u5340\u57df<\/a><\/strong><\/p>\n

\u7d30\u80de\u56e0\u5b50(Cytokine)\u529f\u80fd<\/strong><\/p>\n

\u7d30\u80de\u56e0\u5b50(Cytokine)\u5177\u6709\u591a\u7a2e\u751f\u7269\u5b78\u529f\u80fd\u3002\u5b83\u662f\u6025\u6027\u671f\u53cd\u61c9(acute phase response)\u7684\u6709\u6548\u8a98\u5c0e\u5291\u3002\u5728B\u7d30\u80de(B-cells)\u6700\u7d42\u5206\u5316\u70baIg\u5206\u6ccc\u7d30\u80de(Ig-secreting cells)\u7684\u6700\u7d42\u5206\u5316\u4e2d\u8d77\u91cd\u8981\u4f5c\u7528\uff0c\u53c3\u8207\u6dcb\u5df4\u7d30\u80de(lymphocyte)\u548c\u55ae\u6838\u7d30\u80de(monocyte)\u7684\u5206\u5316\u3002\u5b83\u8a98\u5c0e\u9aa8\u9ad3\u7624(myeloma)\u548c\u6f3f\u7d30\u80de\u7624(plasmacytoma growth)\u751f\u9577\uff0c\u4e26\u8a98\u5c0e\u795e\u7d93\u7d30\u80de\u5206\u5316(differentiation)\u3002\u4f5c\u7528\u65bcB\u7d30\u80de(B-cells)\uff0cT\u7d30\u80de(T-cells)\uff0c\u809d\u7d30\u80de(hepatocytes)\uff0c\u9020\u8840\u7956\u7d30\u80de(hematopoeitic progenitor cells)\u548cCNS\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u7d30\u80de\u3002\u4e5f\u53ef\u4ee5\u4f5c\u70ba\u808c\u8089\u56e0\u5b50(myokine)\u3002\u5b83\u5728\u808c\u8089\u6536\u7e2e\u5f8c\u6392\u5165\u8840\u6db2\uff0c\u4e26\u8d77\u5230\u589e\u52a0\u8102\u80aa\u5206\u89e3\u548c\u6539\u5584\u80f0\u5cf6\u7d20\u62b5\u6297(insulin resistance)\u7684\u4f5c\u7528\u3002<\/p>\n

\u708e\u6027\u7d30\u80de\u56e0\u5b50<\/strong><\/span><\/p>\n

\u708e\u75c7\u7531\u591a\u7a2e\u53ef\u6eb6\u6027\u56e0\u5b50\u4ecb\u5c0e\uff0c\u5305\u62ec\u4e00\u7d44\u7a31\u70ba\u7d30\u80de\u56e0\u5b50\u7684\u5206\u6ccc\u591a\u80bd\u3002\u708e\u6027\u7d30\u80de\u56e0\u5b50\u53ef\u5206\u70ba\u5169\u985e\uff1a\u53c3\u8207\u6025\u6027\u708e\u75c7\u7684\u7d30\u80de\u56e0\u5b50\u548c\u8ca0\u8cac\u4efb\u7684\u7d30\u80de\u56e0\u5b50\u3002\u708e\u75c7\u662f\u7d44\u7e54\u5c0d\u640d\u50b7\u7684\u53cd\u61c9\uff0c\u5176\u7279\u5fb5\u662f\u5728\u6025\u6027\u671f\u4ee5\u589e\u52a0\u7684\u8840\u6d41\u91cf\u548c\u8840\u7ba1\u901a\u900f\u6027\u4ee5\u53ca\u9ad4\u6db2\uff0c\u767d\u7d30\u80de\u548c\u708e\u6027\u4ecb\u8cea\uff08\u4f8b\u5982\u7d30\u80de\u56e0\u5b50\uff09\u7684\u7a4d\u7d2f\u70ba\u7279\u5fb5\u3002\u5e7e\u7a2e\u7d30\u80de\u56e0\u5b50\u5728\u4ecb\u5c0e\u6025\u6027\u708e\u75c7\u53cd\u61c9\u4e2d\u8d77\u95dc\u9375\u4f5c\u7528\uff0c\u5373IL-1\uff0cTNF-\u03b1\uff0cIL-6\uff0cIL-11\uff0cIL-8\u548c\u5176\u4ed6\u8da8\u5316\u56e0\u5b50\uff0cG-CSF\u548cGM-CSF\u3002<\/p>\n

\u5df2\u77e5\u53ef\u4ecb\u5c0e\u6162\u6027\u708e\u75c7\u904e\u7a0b\u7684\u7d30\u80de\u56e0\u5b50\u53ef\u5206\u70ba\u53c3\u8207\u9ad4\u6db2\u708e\u75c7\u7684\u7d30\u80de\u56e0\u5b50\uff0c\u4f8b\u5982IL-3\uff0cIL-4\uff0cIL-5\uff0cIL-6\uff0cIL-7\uff0cIL-9\uff0cIL-10\uff0cIL- 13\uff0c\u8f49\u5316\u751f\u9577\u56e0\u5b50b\uff08TGF-b\uff09\uff0c\u4ee5\u53ca\u90a3\u4e9b\u6709\u52a9\u65bc\u7d30\u80de\u708e\u75c7\u7684\u56e0\u5b50\uff0c\u4f8b\u5982IL-1\uff0cIL-2\uff0cIL-3\uff0cIL-4\uff0cIL-7\uff0cIL-9\uff0cIL-10\uff0c IL-12\uff0c\u5e72\u64fe\u7d20\uff08IFN\uff09\uff0cIFN-g\u8a98\u5c0e\u56e0\u5b50\uff08IGIF\uff09\uff0cTGF-b\u548cTNF-a\u548c-b\u3002\u708e\u75c7\u7570\u5e38\u662f\u4e00\u5927\u985e\u75be\u75c5\uff0c\u662f\u8a31\u591a\u4eba\u985e\u75be\u75c5\u7684\u57fa\u790e\u3002\u7d30\u80de\u56e0\u5b50\u662f\u5bbf\u4e3b\u5c0d\u611f\u67d3\uff0c\u514d\u75ab\u53cd\u61c9\uff0c\u708e\u75c7\u548c\u5275\u50b7\u53cd\u61c9\u7684\u8abf\u7bc0\u5291\u3002\u4e00\u4e9b\u7d30\u80de\u56e0\u5b50\u8d77\u4f7f\u75be\u75c5\u60e1\u5316\u7684\u4f5c\u7528\uff08\u4fc3\u708e\u7d30\u80de\u56e0\u5b50\uff09\uff0c\u800c\u53e6\u4e00\u4e9b\u7d30\u80de\u56e0\u5b50\u8d77\u6e1b\u8f15\u708e\u75c7\u548c\u4fc3\u9032\u7652\u5408\u7684\u4f5c\u7528\uff08\u6297\u708e\u7d30\u80de\u56e0\u5b50\uff09\u3002<\/p>\n

\u767d\u4ecb\u7d20-1\uff08Interleukin-1, IL-1\uff09\u662f\u6709\u53f2\u4ee5\u4f86\u6700\u65e9\u7684\u7d30\u80de\u56e0\u5b50(cytokines)\u4e4b\u4e00\u3002\u5b83\u7684\u6700\u521d\u767c\u73fe\u662f\u53ef\u80fd\u8a98\u767c\u767c\u71d2(fever)\uff0c\u63a7\u5236\u6dcb\u5df4\u7d30\u80de(lymphocytes)\uff0c\u589e\u52a0\u9aa8\u9ad3\u7d30\u80de\u6578\u91cf(bone marrow cells)\u4e26\u5f15\u8d77\u9aa8\u95dc\u7bc0\u9000\u5316\u7684\u56e0\u7d20\u3002\u6b64\u6642\uff0cIL-1\u4ee5\u5176\u4ed6\u5e7e\u7a2e\u540d\u7a31\u70ba\u4eba\u6240\u77e5\uff0c\u5305\u62ec\u5167\u6e90\u6027\u71b1\u539f(endogenous pyrogen)\uff0c\u6dcb\u5df4\u7d30\u80de\u6d3b\u5316\u56e0\u5b50(lymphocyte activating factor)\uff0c\u9020\u8840\u7d20-1(haemopoetin-1)\u548c\u55ae\u6838\u7d30\u80de\u56e0\u5b50(mononuclear cell factor)\u7b49\u3002\u5927\u7d04\u57281984\u5e74\u81f31985\u5e74\u9593\uff0c\u79d1\u5b78\u5bb6\u5011\u8b49\u5be6IL-1\u5be6\u969b\u4e0a\u7531\u5169\u7a2e\u4e0d\u540c\u7684\u86cb\u767d\u8cea\u7d44\u6210\uff0c\u73fe\u5728\u7a31\u70baIL-1\u03b1\u548cIL-1\u03b2\uff0c\u5b83\u5011\u5c6c\u65bc\u7a31\u70ba\u767d\u7d30\u80de\u4ecb\u7d201\u8d85\u5bb6\u65cf\u7684\u7d30\u80de\u56e0\u5b50\u5bb6\u65cf\u3002 IL-1\u03b2\u7531\u5de8\u566c\u7d30\u80de(macrophages)\uff0c\u55ae\u6838\u7d30\u80de(monocytes)\u548c\u6a39\u7a81\u72c0\u7d30\u80de(dendritic cells)\u7522\u751f\u3002<\/p>\n

IFN-\u03b3\uff08IFN-gamma, \u5e72\u64fe\u7d20-\u03b3\uff09\u662f\u4fc3\u708e(proinflammatory)\u7d30\u80de\u56e0\u5b50(cytokine)\u7684\u539f\u578b(prototype)\uff0c\u7531\u591a\u7a2e\u514d\u75ab\u7d30\u80de(immune cells)\u5728\u708e\u6027(inflammatory)\u689d\u4ef6\u4e0b\u7522\u751f\uff0c\u7279\u5225\u662f\u7531T\u7d30\u80de(T cells)\u548cNK\u7d30\u80de(NK cells)\u7522\u751f\u3002\u5b83\u901a\u904e\u4fc3\u9032Th1\u7d30\u80de\u7684\u767c\u80b2(development)\u548c\u6fc0\u6d3b(activation)\uff0c\u55ae\u6838\u7d30\u80de(monocytes)\u548c\u5de8\u566c\u7d30\u80de(macrophage)\u7684\u5316\u5b78\u5f15\u8a98(chemoattraction)\u548c\u6fc0\u6d3b(activation)\uff0c\u6297\u539f\u5448\u905e\u5206\u5b50(antigen presentation molecules)\u7684\u4e0a\u8abf\u4ee5\u53caB\u7d30\u80de\u4e2d\u7684\u514d\u75ab\u7403\u86cb\u767d\u985e\u5225\u8f49\u63db(immunoglobulin class switching)\uff0c\u5728\u5bbf\u4e3b\u9632\u79a6\u4e2d\u8d77\u95dc\u9375\u4f5c\u7528\u3002\u5b83\u9084\u5177\u6709\u6297\u75c5\u6bd2(antiviral)\uff0c\u6297\u589e\u6b96(antiproliferative)\u548c\u51cb\u4ea1\u4f5c\u7528(apoptotic)\u3002\u53e6\u5916\uff0cIFN-\u03b3\u901a\u904e\u4fc3\u9032\u8abf\u7bc0\u6027T\u7d30\u80de\u7684\u767c\u80b2\u4e26\u6291\u5236Th17\u7d30\u80de\u5206\u5316\u800c\u5145\u7576\u6297\u708e\u4ecb\u8cea\u3002 IFN-\u03b3\u4e8c\u805a\u9ad4\u901a\u904e\u5169\u500bIFN-\u03b3R1\u548c\u5169\u500bIFN-\u03b3R2\u4e9e\u57fa\u7684\u53d7\u9ad4\u8907\u5408\u7269\u767c\u51fa\u4fe1\u865f\u3002<\/p>\n

\u767d\u7d30\u80de\u4ecb\u7d2017 (Interleukin 17, IL17)<\/p>\n

IL-17\u57fa\u56e0\u7de8\u78bc( IL-17 gene)\u7684\u86cb\u767d\u8cea\u662f\u7531\u6d3b\u5316\u7684T\u7d30\u80de(activated T cells)\u6240\u7522\u751f\u7684\u4fc3\u767c\u708e\u7d30\u80de\u6fc0\u7d20\u3002\u6b64\u7d30\u80de\u6fc0\u7d20\u8abf\u7bc0 NF-\u03baB \u548c\u7d72\u88c2\u539f\u6d3b\u5316\u86cb\u767d\u6fc0\u9176(mitogen-activated protein kinases)\u7684\u6d3b\u6027\u3002\u9019\u7a2e\u7d30\u80de\u6fc0\u7d20(cytokine )\u53ef\u4ee5\u523a\u6fc0 IL6 \u548c\u74b0\u6c27\u5408\u9176-2 (cyclooxygenase-2, PTGS2\/COX-2) \u7684\u8868\u9054\uff0c\u4e26\u589e\u5f37\u4e00\u6c27\u5316\u6c2e (nitric oxide, NO) \u7684\u7522\u751f\u3002\u9ad8\u6c34\u5e73\u7684\u9019\u7a2e\u7d30\u80de\u6fc0\u7d20\u8207\u591a\u7a2e\u6162\u6027\u767c\u708e\u6027\u75be\u75c5\u6709\u95dc\uff0c\u5305\u62ec\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(rheumatoid arthritis)\u3001\u725b\u76ae\u766c(psoriasis )\u548c\u591a\u767c\u6027\u786c\u5316\u75c7(multiple sclerosis)\u3002<\/p>\n

\u767d\u8840\u7403\u4ecb\u7d20-8\uff08Interleukin-8, IL8)<\/p>\n

IL-8\u57fa\u56e0\u7de8\u78bc(IL-8 gene)\u7684\u86cb\u767d\u8cea\u662fCXC\u8da8\u5316\u56e0\u5b50\u5bb6\u65cf(CXC chemokine family)\u7684\u6210\u54e1\u3002\u9019\u7a2e\u8da8\u5316\u56e0\u5b50(chemokine )\u662f\u767c\u708e\u53cd\u61c9(inflammatory response)\u7684\u4e3b\u8981\u4ecb\u8cea\u4e4b\u4e00\u3002\u9019\u7a2e\u8da8\u5316\u56e0\u5b50\u7531\u591a\u7a2e\u7d30\u80de\u985e\u578b\u5206\u6ccc\u3002\u5b83\u5177\u6709\u5316\u5b78\u5f15\u8a98\u5291( chemoattractant)\u7684\u4f5c\u7528\uff0c\u4e5f\u662f\u4e00\u7a2e\u6709\u6548\u7684\u8840\u7ba1\u751f\u6210\u56e0\u5b50(angiogenic factor)\u3002 IL-8\u57fa\u56e0\u88ab\u8a8d\u70ba\u5728\u7d30\u652f\u6c23\u7ba1\u708e\uff08\u4e00\u7a2e\u7531\u75c5\u6bd2\u611f\u67d3\u5f15\u8d77\u7684\u5e38\u898b\u547c\u5438\u9053\u75be\u75c5\uff09\u7684\u767c\u75c5\u6a5f\u5236(pathogenesis )\u4e2d\u767c\u63ee\u4f5c\u7528\u3002 IL-8\u57fa\u56e0(IL-8 gene )\u548cCXC\u8da8\u5316\u56e0\u5b50\u57fa\u56e0\u5bb6\u65cf(CXC chemokine gene family)\u7684\u5176\u4ed610\u500b\u6210\u54e1\u5728\u5b9a\u4f4d\u65bc\u67d3\u8272\u9ad44q( chromosome 4q)\u7684\u5340\u57df\u4e2d\u5f62\u6210\u8da8\u5316\u56e0\u5b50\u57fa\u56e0\u7c07(chemokine gene cluster )\u3002<\/p>\n

<\/p>\n